As a first step towards HIV cure, we assessed a strategy of antiretroviral therapy (ART) intensification followed by interleukin-7 (IL-7) used as an HIV-reactivating agent.
A multicentre, randomized clinical trial included patients on suppressive ART with CD4+ cell counts at least 350/μl and HIV-DNA between 10 and 1000 copies/106 peripheral blood mononuclear cells (PBMCs). After an 8-week raltegravir and maraviroc intensification, patients were randomized to intensification alone or with 3 weekly IL-7 injections at weeks 8, 9 and 10. The primary endpoint was at least 0.5 log10 decrease in HIV-DNA in PBMC at W56. Secondary endpoints included ultrasensitive plasma viremia, immunologic changes and safety.
Twenty-nine patients were enrolled with median baseline 558 CD4+ cell counts/μl, 360 HIV-DNA copies/106 PBMCs and 12 years on ART. No patient in either arm achieved the primary endpoint. Addition of IL-7 induced a significant expansion of CD4+ T cells, primarily central-memory cells (+5%, P = 0.001) at week 12, together with an increase in levels of HIV-DNA/106 PBMC (+0.28 log10 copies/P = 0.001), and the proportion of patients with detectable ultrasensitive plasma HIV-RNA increased compared with week 8 (P = 0.07). At weeks 56 and 80, total and memory CD4+ cell counts and total HIV-DNA/ml of blood remained elevated. In contrast, HIV-DNA/million PBMC and plasma viremia returned to baseline levels whereas activated HLA-DR+CD4+ T cells significantly decreased.
IL-7 administration and dual ART intensification induced, despite a mild HIV reactivation, an amplification of the HIV reservoir, as a result of central-memory CD4+ T-cell expansion, thus limiting this IL-7 based strategy.
This trial was registered with ClinicalTrials.gov, number NCT01019551.
aAP-HP, Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, Paris
bSorbonne Universités, UPMC Univ Paris 06
cINSERM, UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris
dAP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris
eORVACS, Hôpital Pitié-Salpêtrière, Paris
fINSERM, UMR_S 1135, CIMI, Paris, France
gSan Raffaele Scientific Institute, Milan, Italy
hIrsi Caixa, Foundation. UAB, UVIC-UCC Hospital ‘Germans Trias i Pujol’, Badalona, Catalonia, Spain
iRoyal Free and University College London Medical School, London, UK
jCenter for Global Health and Department of Medicine, Northwestern University, Chicago, Illinois, USA
kAP-HP, Hôpital Pitié-Salpêtrière, Service d’immunologie, Paris, France.
Correspondence to Christine Katlama, MD, AP-HP, Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, 43/83, boulevard de l’hôpital, 75013, Paris, France. Tel: +33 1 42 16 01 42; fax: +33 1 42 16 01 66; e-mail: firstname.lastname@example.org
Received 2 March, 2015
Revised 24 May, 2015
Accepted 3 June, 2015
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).